Morgan Stanley Fibrogen Inc Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Fibrogen Inc stock. As of the latest transaction made, Morgan Stanley holds 97,744 shares of FGEN stock, worth $30,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,744

Previous 37,958 157.51%

Holding current value

$30,300

Previous $20,000 50.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.31 - $0.77 $18,533 - $46,035	59,786 Added 157.51%	97,744 $30,000
Q4 2024 Feb 14, 2025	SELL	$0.3 - $0.58 $1,128 - $2,180	-3,760 Reduced 9.01%	37,958 $20,000
Q3 2024 May 14, 2025	SELL	$0.33 - $1.26 $64,270 - $245,395	-194,758 Reduced 82.36%	41,718 $16,000
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $64,270 - $245,395	-194,758 Reduced 82.36%	41,718 $16,000
Q2 2024 May 14, 2025	BUY	$0.89 - $2.36 $176,681 - $468,502	198,518 Added 522.99%	236,476 $210,000
Q2 2024 Oct 17, 2024	SELL	$0.89 - $2.36 $112,844 - $299,229	-126,792 Reduced 34.9%	236,476 $210,000
Q2 2024 Aug 14, 2024	SELL	$0.89 - $2.36 $112,844 - $299,229	-126,792 Reduced 34.9%	236,476 $210,000
Q1 2024 Oct 17, 2024	BUY	$0.73 - $2.73 $92,558 - $346,142	126,792 Added 53.62%	363,268 $853,000
Q1 2024 Aug 16, 2024	SELL	$0.73 - $2.73 $330,877 - $1.24 Million	-453,257 Reduced 55.51%	363,268 $853,000
Q1 2024 May 15, 2024	SELL	$0.73 - $2.73 $330,877 - $1.24 Million	-453,257 Reduced 55.51%	363,268 $853,000
Q4 2023 Aug 16, 2024	BUY	$0.38 - $0.91 $220,418 - $527,844	580,049 Added 245.29%	816,525 $726,000
Q4 2023 Feb 13, 2024	SELL	$0.38 - $0.91 $221,340 - $530,052	-582,475 Reduced 41.64%	816,525 $726,000
Q3 2023 Nov 15, 2023	BUY	$0.79 - $2.83 $593,761 - $2.13 Million	751,597 Added 116.09%	1,399,000 $1.2 Million
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $524,999 - $4.34 Million	-210,843 Reduced 24.57%	647,403 $1.75 Million
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $6.22 Million - $9.83 Million	390,249 Added 83.39%	858,246 $16 Million
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $1.69 Million - $2.26 Million	127,663 Added 37.51%	467,997 $7.5 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $3.54 Million - $4.53 Million	-310,432 Reduced 47.7%	340,334 $4.43 Million
Q2 2022 Oct 27, 2022	BUY	$7.94 - $12.96 $895,909 - $1.46 Million	112,835 Added 20.98%	650,766 $6.87 Million
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $895,909 - $1.46 Million	112,835 Added 20.98%	650,766 $6.87 Million
Q1 2022 Oct 27, 2022	SELL	$12.02 - $16.79 $1.36 Million - $1.89 Million	-112,835 Reduced 17.34%	537,931 $6.47 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.79 $3.11 Million - $4.34 Million	258,473 Added 92.49%	537,931 $6.47 Million
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $644,794 - $999,334	-64,934 Reduced 18.85%	279,458 $3.94 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $3.51 Million - $9.17 Million	344,392 New	344,392 $3.52 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

34.6M

Call Options Held

461K

Put Options Held

102K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $29.1M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account